ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.

Kathryn Evans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.